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Objectives. The aim of the present study was to review the published literature in order to identify relevant studies for inclusion and
to determine whether there was any evidence on the clinical effectiveness of selected desensitizing toothpastes, calcium sodium
phosphosilicate (CSPS), amorphous calcium phosphate (ACP), nanohydroxyapatite, and casein phosphopeptide-amorphous
calcium phosphate (tooth mousse) on reducing dentine hypersensitivity (DH).Materials and Methods. Following a review of 593
papers identified from searching both electronic databases (PUBMED) and hand searching of relevant written journals, only 5
papers were accepted for inclusion. Results. Analysis of the included studies (3 CSPS and 2 ACP) would suggest that there may be
some benefit for patients using these products for reducing DH. No direct comparative studies were available to assess all these
products under the same conditions neither were there any comparative randomised controlled studies that compared at least two
of these products in determining their effectiveness in treating DH.Conclusions. Due to the small number of included studies, there
are limited clinical data to support any claims of clinical efficacy of these OTC products. Further studies are therefore required to
determine the efficacy of these products in well-controlled RCT studies with a larger sample size.
1. Introduction
Dentine hypersensitivity (DH) is a worldwide clinical condi-
tion that has been reported to have an impact on the adult
population at various stages during their lifetime. Recently,
several investigators [1, 2] reported on the negative effects of
DH on a patient’s quality of life (oral health-related quality of
life, OHRQoL). The prevalence of DH reported in the litera-
ture varies depending on the methodology utilized to collect
data; however, it has been reported to affect up to 74% of the
population although several investigators have reported that
this figure may be higher in individuals with periodontal dis-
ease [3, 4]. According to a number of investigators [5, 6], DH
appears to have been previously underreported by patients as
well as underdiagnosed by dentists which therefore may lead
to the problem being ignored and undertreated. Diagnosis of
DH can be problematic but from the clinician’s viewpoint, it
is essential to exclude all other clinical conditions that have a
similar pain history.
The management of generalized mild or moderate DH
has traditionally been achieved via the use of over-the-
counter (OTC) desensitising products through a clinician’s
recommendations which depend on the nature of its active
ingredient that may take up to 2–4 weeks to achieve some
resolution of the pain associated with DH.There is a plethora
of remedies currently available for both OTC and in-office
alleviation of DH, however none of these products appear to
be the “gold standard” in providing a long term effective treat-
ment to the problem [5, 7, 8]. Marketed products currently
work either via their tubule occlusion properties, for exam-
ple, calcium sodium phosphosilicate (CSPS [Novamin]),
amorphous calcium phosphate (ACP), nanohydroxyapatite
(HAP), and tooth mousse or via nerve desensitization, for
example, potassium technology [7, 8].
One of the problems however in evaluating the reported
efficacy of both OTC and in-office products was that while
there were reported claims of either immediate or long lasting
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effectiveness, there were limited clinical data to support these
claims under standardized clinical procedures.
2. Aims and Objectives
The aim of the present study was to critically review the
available published literature in order to identify all relevant
studies for inclusion and to determine whether there was any
evidence on the clinical effectiveness of selected over-the-
counter (OTC) toothpastes, calcium sodium phosphosilicate
(CSPS [Novamin]), amorphous calcium phosphate (ACP),
nanohydroxyapatite (HAP), and tooth mousse dentifrices on
reducing dentine hypersensitivity (DH).
3. Methodology
The search methodology used for the current review was
a modified version of the Cochrane systematic review by
Poulsen et al. [9] and Karim and Gillam [7].
3.1. Selection Criteria
3.1.1. Types of Study. This review will include all full text,
double-blinded, randomized controlled trials (RCT) con-
ducted in vivo to assess the efficacy of any of the desensitizing
agents named above and their effect on DH. The duration of
the included studies should be at least 6 weeks in duration.
3.1.2. Types of Subjects. The subjects included in the relevant
studies are dentate, healthy adults (of at least 18 years of age)
with a reported and established DH diagnosis. Studies were
excluded if the sample in the original study was not described
or if the subjects included into the study had received
periodontal treatment within the period of the trial or if the
participants are/were undertaking anti-inflammatory treat-
ment due to medical problems. The number of participant
dropouts and reason for dropout should be included in the
study.
3.1.3. Types of Outcome Measurement. Assessing DH at base-
line and after treatment with a desensitizing agent would be
an ideal way of comparing data andDHprevalence reduction
if any. DH can be measured via numerous methods, for
example, tactile, thermal or evaporative stimuli, patient ques-
tionnaires, and so forth.The included studies will incorporate
a detailed explanation of
(i) history of DH as assessed at baseline data by at least
one recognized methodology (tactile, thermal);
(ii) history of DH as assessed following desensitizer use.
3.1.4. Types of Intervention. The participants were randomly
allocated to individual groups receiving one of the following:
(a) test desensitizer (% concentration of desensitizer
should be stated by the authors);
(b) negative control (same as test group however lacking
the active ingredient (minus active ingredient)).
The ideal negative control group would entail the usage of a
toothpaste of the same composition as the test desensitizer
however lacking the active ingredient under test. Studies
were included if fluoride was absent or present (at same
concentration) in both groups. Studies were excluded if the
test toothpaste contained fluoride whereas the control did
not. Studies were accepted into the present review if the
above criteria of both groups (a) and (b) were met; other
groups (e.g., groups C, D, etc.) testing different percentage of
desensitizers were acceptable provided that a negative control
was established.
3.1.5. Other Relevant Criteria
(i) Investigator calibration on assessment of DH.
(ii) Statistical analysis.
(iii) Randomization of the participants into different
groups was clearly described, concealment of par-
ticipant group allocation to both investigators and
subjects.
4. Search Strategy
The search strategy was included using electronic databases
(e.g., PUBMED) and hand searching up to 31, December,
2012. Hand searching included examining the relevant pub-
lished or incomplete journals in English. The searching
keywords in PUBMED were (dentifrice OR dentifrices) OR
(toothpaste OR toothpastes OR tooth paste) OR (desensit∗)
AND (agent OR efficacy OR effect) AND (dentin OR dentine
or tooth OR teeth OR root∗) AND (Hypersensitivity OR
hypersensit∗ OR sensitivity OR sensitiv∗ OR over-sensit∗)
NOT (laser∗ OR adhesiv∗ OR endodont∗ OR bleach∗ or
whitening OR bond∗ OR caries)
(i) AND (hydroxy apatite OR nanohydroxyapatite OR
nano HAP OR nHAP).
(ii) AND (casein phosphopeptide amorphous calcium
phosphate OR CPP-ACP).
(iii) AND (amorphous calcium phosphate OR ACP).
5. Statistical Analysis
Statistical analysis of the data from these studies was not
attempted due to the variations in the study design, method-
ology, study duration, and reporting of the pain response
(percentages, VAS scores, or pain categories, etc.).
6. Method of the Review
(Data Collection and Analysis)
A review of the abstracts and titles was carried out by one
of the reviewers (E. T.) who then obtained copies of all the
relevant studies where available. Two reviewers (E. T. and D.
G.) subsequently sought to determine the eligibility of the
papers and data extraction. Any differences as to the inclusion
or exclusion of articles were resolved following discussion
between the two reviewers.
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6.1. Quality Assessment of the Included Studies. The method-
ological quality of the studies included in the review was
assessed according to the criteria of concealment of treatment
allocation described in the Cochrane Handbook for System-
atic Review of Intervention [10].
The acceptance and rejection criteria for the inclusion
of relevant studies for the present review were discussed
between the two reviewers (E. T. and D. G.) prior to the
collation of papers.
7. Results
7.1. Overall Description of the Included and Excluded Stud-
ies. Following the initial screening of identified articles
for the present review, there were 593 potentially relevant
studies found by searching either the electronic databases
(PUBMED-574 titles) or by hand searching (19 relevant titles)
articles from the literature. Unpublished studies were found
by searching the electronic databases or by hand searching.
57 studies were regarded as relevant for this review while 536
were excluded. The 57 studies were grouped into Novamin
papers comprising of 34 studies, ACP papers comprising
10 studies, HAP papers comprising of 11 studies, and CPP-
ACP/tooth mousse papers comprising of 2 studies (Figure 1).
Following an evaluation of the various papers, of the
34 Novamin studies, 31 studies were excluded and 3 were
included (Table 1), of the 10 ACP relevant studies, two studies
were included and eight studies were excluded (Table 2),
of the 11 HAP relevant studies, all studies were excluded
(Table 3), of the 2 CPP-ACP relevant studies, all studies were
excluded (Table 4).
7.2. Excluded Studies
7.2.1. Novamin Studies. There were 15 studies which were
excluded as these were in vitro investigations and therefore
did not meet the inclusion criteria [11–25]. Of the 19 remain-
ing studies, one review was also excluded [26] and three
were excluded as they were reported as an abstract [27–29].
One study was excluded as the full published article was
in Chinese and only the abstract was in English [30]. Two
further studies were excluded as Novamin was used as an in
office agent (desensitizing polishing paste) and not as anOTC
desensitizing toothpaste [31, 32]. One study was excluded
due to its duration of ≤10 days [33] and a further study was
excluded due its aims; for example, Tai et al. [33] investigated
the antigingivitis effect of Novamin on the gingival tissues
(and not as a desensitizing toothpaste per se) and therefore
the study was considered irrelevant to this review. Of the
remaining ten studies, three were excluded as the publication
date was after December 31st [34–36]; the Neuhaus study [37]
evaluated a In office professionally applied polishing paste,
whereas the other two studies lacked a negative control in the
clinical trial designmethodology [35, 36]. Two further studies
were excluded since the negative control group contained
fluoride whereas the test group (Novamin) did not [38, 39].
One study was excluded because the dentine specimens were
placed in intraoral appliances worn by patients to establish
an in situ effect of Novamin [40]. One further study was
excluded due to the lack of description on the composition
of the control randomization [41] (Table 1).
7.2.2. ACP Studies. Four studies were excluded as these were
in vitro investigations examining the effects of ACP on
dentine tubule occlusion [42–45]. One study was excluded
since the control group contained sodium fluoride (NaF) and
the test group did not [46]. The Giniger et al. [47] study
was excluded due to the investigators examining DH as a
result of vital bleaching which may be considered to be a
distinct mechanism from DH [48]. Geiger et al.’s [49] study
was excluded due to the lack of a negative control (the control
group was a Potassium Chloride (KCl) product) and the final
excluded study by Yates et al. [50] was excluded since theACP
was applied as an in-office agent and not as anOTC dentifrice
(Table 2).
7.2.3. HAP Studies. There were eight studies which were
excluded because they were in vitro investigations and did
not meet the inclusion criteria [51–58]. Another study was
excluded since the HAP was used as an in-office agent
rather than a toothpaste [59] whereas Orsini et al.’s [60]
study was excluded due to the lack of a negative control
being used. The final excluded study [61] was excluded due
to the investigators examining the effect of HAP on DH
following dental bleaching, which as previously indicatedwas
suggested to have a different mechanism to that described for
DH [48] (Table 3).
7.2.4. CPP-ACP Studies. Two studies were excluded since
these were in vitro investigations investigating the effect of
CPP-ACP on dentine tubule occlusion [62, 63]. No other
studies related to DH were retrieved as a result of the search
strategy for the present review (Table 4).
7.3. Analysis of the Included Studies
7.3.1. Study Design. The five included studies in the present
review comprised of randomized controlled trials (three
for Novamin and two for ACP) (Tables 5 and 6). Pradeep
et al. [64] was a triple-blinded, randomized controlled trial.
Randomization was generated via a random computer table
and the investigators were not involved in this procedure
to ensure their blinding. Participants, investigators, and
statisticians were blinded and the toothpastes were placed
in white tubes labelled A, B, C, and D so that allocation
concealment was established. The Pradeep and Sharma [65]
study was also a triple-blinded randomized controlled trial.
Triple blindness was established via dispensing toothpastes
in identical tubes which were coded.The true identity of each
tubewas only confirmed (breaking of the codes) following the
final clinical assessment by these investigators.The Litkowski
and Greenspan [66] study was a double-blinded randomized
controlled trial; however, details on randomization of both
subjects and products were not provided in the paper.
Ghassemi et al. [67] stratified their subjects into VAS,
age, and gender and then randomly allocated them into three
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Screening potentially relevant articles by electronic
databases and hand searching; 593 studies (in
English) were retrieved
Initial screening 536 articles were rejected
57 articles were included
2nd screening
52 articles were excluded
5 articles were included
Figure 1: The flow diagram of the study selection process.
groups which were representative of the sample. Allocation
concealment was achieved by dispensing toothpastes in
identical tubes, the identity of which was not revealed to par-
ticipants or investigators until the end of the study. No details
were provided as to how and bywhom the randomization and
allocation concealment process was conducted.
The Kaufman et al. [68] study was a double-blind ran-
domized controlled trial; subjects were stratified according
to prognostic measures, tactile scores for sensitive teeth, the
number of sensitive teeth per subject, and the proportion of
sensitive teeth per subject. Subjects in each group were then
provided with one of the three treatment modalities.
7.3.2. Study Population. The participants fulfilling the inclu-
sion criteria for Pradeep et al. [64] and Pradeep and Sharma
[65] reported a history of DH as a result of subjects exhibiting
either gingival recession or cervical abrasion. Subjects were
required to have at least two teeth with a VAS of 4 or
more in order to be included into the study. Teeth included
were included provided that they had either small or no
occlusal restorations. Teethwith caries, defective restorations,
and orthodontic appliances or bridgework were excluded.
Participants for these two studies were also excluded if they
were allergic to any of the ingredients of the toothpastes tested
or suffering from chronic diseases, oral pathology, and eating
disorders for which they were taking anti-inflammatory
medications or analgesics.
The former paper recruited 160 subjects; however, only
149 completed the study; 72 males and 77 females. The latter
paper recruited 120 participants of which 110 completed the
study; 58 males and 52 females.
Litkowski and Greenspan [66] recruited healthy male
and female adults suffering from DH who were not using
a desensitizing agent at the time of the study. Participants
suffering frommedical conditions, takingmedications which
may interfere with pain perception or response, or allergic to
any of the toothpastes used in the studywere excluded. A total
of 66 subjects were recruited in the study however no details
were forthcoming regarding gender or age of subjects.
Ghassemi and coworkers [67] recruited 208 participants
in order that at least 100 subjects in each group would
complete the study.The inclusion and exclusion criteria were
clearly described in the study; subjects with severe peri-
odontal disease, gross oral neglect, periodontal, restorative,
or orthodontic treatment within the last three months or
dental prophylaxis within the last two weeks. Subjects were
also excluded if they were suffering from postbleaching tooth
sensitivity or were taking medications which would interfere
with pain perception.
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Table 1: Characteristics of Novamin containing toothpastes excluded studies.
Number Study Reason
1 Bakry et al. [11] In vitro investigation
2 Burwell et al. [12] In vitro investigation
3 Burwell et al. [13] In vitro investigation
4 Chiang et al. [14] In vitro investigation
5 Earl et al. [15] In vitro investigation
6 Farmakis et al. [16] In vitro investigation
7 Gillam et al. [17] In vitro investigation
8 Gjorgievska and Nicholson [18] In vitro investigation
9 Golpayegani et al. [19] In vitro investigation
10 Mitchell et al. [20] In vitro investigation
11 Mneimne et al. [21] In vitro investigation
12 Parkinson et al. [22] Abstract only (at the time of collection of papers). However as the study lacked a negative controlin the clinical trial design methodology it was excluded from the present review
13 Sauro et al. [23] In vitro investigation
14 Wang et al. [24] In vitro investigation
15 Wang et al. [25] In vitro investigation
16 Greenspan [26] Review
17 Du et al. [27] No mention of randomisation and allocation concealment methods
18 Patsouri et al. [28] Abstract only
19 Surve et al. [29]
Abstract only (at the time of collection of papers). However the study investigated the
combination of an In-office application with or without a OTC desensitizing toothpaste following
periodontal treatment and was therefore considered irrelevant for the present review
20 Yu et al. [30] Publication in Chinese (Abstract in English)
21 Milleman et al. [31] In-office agent (professionally applied polishing paste) and not as an OTC desensitizing toothpaste
22 Narongdej et al. [32] Novamin used as in-office agent
23 Banerjee et al. [33] Study duration ≤10 days
24 Tai et al. [37] Investigated the antigingivitis effect of Novamin on the gingival tissues (desensitizing toothpasteper se) and therefore the study was considered irrelevant to this review
25 Acharya et al. [34] Excluded as the publication date was after December 31st and lacked a negative control in theclinical trial design methodology
26 Ananthakrishna et al. [35] Excluded as the publication date was after December 31st and lacked a negative control in theclinical trial design methodology
27 Neuhaus et al. [36] Excluded as the publication date was after December 31st and evaluated an In-office agent(professionally applied polishing paste)
28 Salian et al. [38] The negative control group contained fluoride whereas the test group (Novamin) did not
29 Sharma et al. [39] The negative control group contained fluoride whereas the test group (Novamin) did not
30 West et al. [40] The dentine specimens were placed in intraoral appliances worn by patients to establish an in situeffect of Novamin
31 Rajesh et al. [41] One further study was excluded due to the lack of description on the composition of the controlrandomization
Kaufman et al. [68] recruited 105 healthy subjects with
at least one sensitive tooth to either scratching with a dental
explorer, a one-second air blast, or both stimuli. Teeth with
caries, cracks or large restorations were excluded; subjects
who have used a desensitizing toothpaste within the last
6 weeks prior to the study were also excluded. Kaufman
and coworkers [68] however only examined canines and
premolars for inclusion in the study.
7.3.3. Age Range of Participants. Participants’ age ranged from
20 to 60 years of age with a mean of 39.9 years [64]. In the
study by Pradeep and Sharma [65] the age ranged between
20 and 60 years with a mean of 39.4 years. Litkowski and
Greenspan [66] however did not state the age range of the
subjects recruited in their study. Ghassemi et al. [67] included
patients within 18–64 years of age. The Kaufman et al. [68]
study did not mention the age range of participants.
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Table 2: Characteristics of ACP containing toothpastes excluded studies.
Number Study Reason
1 Thanatvarakorn et al. [42] In vitro investigation examining the effects of ACP on dentine tubule occlusion
2 Tirapelli et al. [43] In vitro investigation examining the effects of ACP on dentine tubule occlusion
3 Winston et al. [44] In vitro investigation examining the effects of ACP on dentine tubule occlusion
4 Charig et al. [45] In vitro investigation examining the effects of ACP on dentine tubule occlusion
5 Fiocchi et al. [46] Excluded due to the investigators examining DH as a result of vital bleaching
6 Giniger et al. [47] Excluded due to testing effect of agent on vital tooth bleaching
7 Geiger et al. [49] Excluded due to the lack of a negative control (the control group was a KCl product)
8 Yates et al. [50] Excluded since the ACP was applied as an in-office agent and not as an OTC toothpaste
Table 3: Characteristics of HAP containing toothpastes excluded studies.
Number Study Reason
1 Mukai et al. [51] In vitro investigation and did not meet the inclusion criteria
2 Zhang et al. [52] In vitro investigation and did not meet the inclusion criteria
3 Braun et al. [53] In vitro investigation and did not meet the inclusion criteria
4 Lee et al. [54] In vitro investigation and did not meet the inclusion criteria
5 Rimondini et al. [55] In vitro investigation and did not meet the inclusion criteria
6 Yuan et al. [56] In vitro investigation and did not meet the inclusion criteria
7 Tschoppe et al. [57] In vitro investigation and did not meet the inclusion criteria
8 Akatsuka et al. [58] In vitro investigation and did not meet the inclusion criteria
9 Shetty et al. [59] Excluded an in-office agent rather than a toothpaste
10 Orsini et al. [60] Excluded due to the lack of a negative control being used
11 Browning and Deschepper Maed [61] Excluded due to the investigators examining the effect of HAP on DH following dentalbleaching
7.3.4. Study Duration. The ideal duration for most clinical
trials assessing the efficacy of a desensitizing agent has been
considered to be eight weeks; however, Holland et al. [69]
reported that the “optimum time course for different agents,
differs based on their action.” Studies were of similar duration
ranging from six to eight weeks; Pradeep et al. [64] and
Pradeep and Sharma [65] studies lasted six weeks and the
DH assessment was recorded at baseline, two, and six weeks.
The Litkowski and Greenspan [66] study lasted eight weeks
and DH assessment was conducted at baseline, two, four, and
eight weeks posttreatment time intervals. Ghassemi et al. [67]
study was a two-phase trial in which each phase lasted eight
weeks; DH assessments were conducted at baseline, four, and
eight weeks. Kaufman et al. [68] was an eight-week long trial;
DH assessments were recorded at baseline, three, and eight
weeks after treatment (Table 7).
7.3.5. Statistical Power. Sample size calculations in the
Pradeep et al. [64] and Pradeep and Sharma [65] studies were
performed according to a 30% VAS reduction between test
and control groups with a two-tailed significance level of 5%
and a power of 90%. Litkowski andGreenspan [66] estimated
a sample size of nomore than 10 was required to provide with
a 40% relative efficacy for a test product over a placebo; this
was calculated via a two-tailed alpha of 5% with 80% power.
Ghassemi et al. [67] calculated that a sample size of at least
100 subjects in each group would provide a power of 80% for
detecting a significant difference of 30–35% between group
mean VAS scores. There was no mention of the statistical
power in the Kaufman et al. [68] study.
7.3.6. Randomization and Allocation Concealment. Accord-
ing to Schulz [70], random allocation to intervention groups
in a clinical study appears to be the only method of ensuring
that the groups being compared have an equivalent foothold
at study outset hence eliminating confounding factors or the
introduction of bias into the study. Of the three included
Novamin randomized studies (RCT) studies, only two studies
[64, 65] reported on details on randomization and alloca-
tion concealment. For example, Pradeep et al. [64] used a
computer-generated random table to allocate participants
into four different groups. The investigators of this study
were not involved in the randomization process as the study
statisticianswere responsible for the allocation of participants
into groups and as a consequence were blinded. This study
was therefore considered to be triple-blind in nature and
hence the treatment received by each group was concealed
to everyone involved in the study, namely, investigators,
participants, and statisticians. The codes were only broken
following the completion of the study. Pradeep and Sharma
[65] randomly allocated participants into the three treatment
groups via a lottery method; however, no further explanation
or details were forthcoming from the study. Participants
and investigators however were blinded as to the contents
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Table 4: Characteristics of CPP-ACP containing toothpastes excluded studies.
Number Study Reason
1 Gandolfi et al. [62] In vitro investigation investigating the effect of CPP-ACP on dentine tubule occlusion
2 Ranjitkar et al. [63] In vitro investigation investigating the effect of CPP-ACP on dentine tubule occlusion
Table 5: Characteristics of Novamin containing toothpastes included studies.
Number Studies Methods Participants Interventions Outcomes Results
1 Pradeep et al.[64]
6-week triple-blinded
RCT
149 completing
out of 160
Group A: 5% potassium nitrate
toothpaste
-Group B: 5% calcium sodium
phosphosilicate toothpaste
-Group C: 3.85% amine fluoride
toothpaste
-Group D: placebo toothpaste
(negative control; no information
was provided as to the
constituents of control)
Pre-op and post-op
evaporative
(controlled air
stimulus) and
thermal stimuli
(10mL of ice cold
water) used
5% CSPS > 3.85%
amine fluoride >
KNO3 > placebo
2
Pradeep and
Sharma [65] 6-week triple-blindedRCT
110 completing
out of 120
Group A: 5% calcium sodium
phosphosilicate (Novamin)
toothpaste
-Group B: 5% potassium nitrate
toothpaste (positive control)
-Group C: same formulation as
toothpaste A; however, no active
ingredient (negative control)
Pre-op and post-op
evaporative
(controlled air
stimulus) and
thermal stimuli
(10mL of ice cold
water) used
5% CPS > KNO3 >
placebo
3
Litkowski and
Greenspan
[66]
8-week double-blind
randomized placebo
controlled pilot study
66
No mention of
dropouts
Group A: placebo control
toothpaste (negative control; no
information was provided as to
the constituents of control)
-Group B: 2.5% Novamin
toothpaste
-Group C: 7.5% Novamin
toothpaste
Pre-op and post-op
tactile (Yeaple
probe calibrated at
40 g force) and an
evaporative
stimulus
(one-second air
blast)
7.5% CSPS > 2.5%
CSPS > placebo
of the three identical tubes A, B, and C; contents of each
tube were subsequently revealed to the investigators fol-
lowing the last assessment. Litkowski and Greenspan [66]
failed to disclose any information as to the randomized or
allocation concealment between the different groups in the
study. Ghassemi et al. [67] stratified individuals according to
VAS scores, gender, and age; randomization into the three
groups was carried out according to the strata created so
that three equivalent groups were formed. No detail was
provided regarding who carried out the randomization and
allocation concealment. Kaufman et al. [68] did not mention
any methods of randomization or allocation concealment.
7.3.7. Consideration ofWithdrawals and Dropouts. According
to Bowers [71] withdrawals and dropouts that may occur
following the randomization process may affect the balance
of the groups established via the randomization procedure.
One way of avoiding this problem is by reporting on the
number of withdrawals or dropouts as if they were still a
part of the clinical trial; this is called the intention-to-treat
analysis. Withdrawals and dropouts were reported in all
three included studies; Pradeep and Sharma [65] reported
10 out of 120 whereas Pradeep et al. [64] reported 11 out
of 160 dropped out of the trial; both studies reported the
reason of withdrawal was that participants failed to follow
up or discontinued treatment. Litkowski and Greenspan [66]
reported no dropouts. Ghassemi et al. [67] did not report
on any dropouts during the first phase of the trial; however,
carefully going through the results, it can be observed that
five participants dropped out. During the second phase of
this trial, thirteen participants decided to discontinue the
treatment; no reason was provided by authors. Kaufman et al.
[68] reported four dropouts during the duration of the trial;
the authors however did not report the reason for withdrawal,
but it was recorded that there were no adverse side effects
reported by any of the participants (Table 8).
8. Data Analysis
No further analyses were performed on the mean differences
from 6 to 8 weeks for any other measurement outcomes for
the purpose of meta-analysis.
8.1. Previous History of DH Reported at Baseline. This
included any history of DH in the included studies, reported
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Table 6: Characteristics of ACP containing toothpastes included studies.
Number Studies Methods Participants Interventions Outcomes Results
Ghassemi et
al. [67] 8-week, parallel,double-blind RCT
203 of 208
participants
completed trial
Group A: ACP and 0.24% NaF
Group B: control toothpaste
containing 0.24% NaF
Thermal: cold air blast
(VAS and Schiff tests
recorded)
ACP containing
toothpaste > to
control toothpaste
Kaufman et
al. [68]
8-week
double-blind RCT
101 of 105
participants
completed study
Group A: NaF conventional
OTC control
Group B: 1150 NaF and ACP
Group C: 1150 ppmMFP and
ACP
Electrical (sensitometer)
Tactile (scratchometer)
Evaporative (one-second
air blast)
ACP and NaF >
ACP >MFP >
OTC control
Table 7: Comparison of the duration of the included studies.
Study Duration
Pradeep et al. [64] 6 weeks
Pradeep and Sharma [65] 6 weeks
Litkowski and Greenspan [66] 8 weeks
Ghassemi et al. [67] Phase I: 8 weeks
Phase II: 8 weeks
Kaufman et al. [68] 8 weeks
Table 8: Comparison of dropouts from the included studies.
Study Dropouts/withdrawal Reason forwithdrawal
Pradeep et al. [64] 11 No reason specified
Pradeep and Sharma
[65] 10 No reason specified
Litkowski and
Greenspan [66]
No mention of
dropouts No reason specified
Ghassemi et al. [67] Phase I: 5 No reason specified
Phase II: 13
Kaufman et al. [68] 4 No reason specified
by investigators, in the form of baseline data, which was
confirmed by a response to tactile and/or thermal stimulus.
Minor data analysis variations existed between Pradeep et al.
[64] and Pradeep and Sharma [65]; both studies reported
on the mean VAS of each group at baseline, two, and six
weeks in the presence of air and water stimuli. Pradeep et al.
[64] used a one-way analysis of variance (ANOVA) and 𝑃 <
0.05 was considered to be a statistically significant difference
when detected. Pradeep and Sharma [65] also used post
hoc one-way analysis of variance; however, the Holm-Sidak
method was used (𝑃 < 0.05). Litkowski and Greenspan [66]
also reported on the % reduction of DH from baseline and
included the mean +/− standard error change from baseline.
These investigators also used a one-way analysis of variance
(ANOVA test) on the change of VAS from baseline at two,
four, and eight weeks. Duncan’s multiple range test was used
to rank group differences if the treatment factors were found
to be significant at alpha being equal to 0.05. Ghassemi et al.
[67] presented their results in tabulated and graphical form
which allowed the reader to make the necessary conclusions
from the study. The primary outcome was determined by
comparison of mean VAS scores at the three-interval visits;
analysis of variance (ANOVA) was used to compare baseline
mean VAS scores. Within group differences were calculated
using student’s 𝑡-test for paired data at four and eight weeks.
Differences between the different groups were calculated
using the analysis of covariance (ANCOVA) model. The
secondary outcome of the latter study was determined via the
mean Schiff Thermal Sensitivity Scale score (STSS) at each
of the three exam intervals. Mean STSS scores were used
to calculate Wilcoxon’s signed rank test; this statistical test
was used to evaluate within group differences. Wilcoxon’s
rank sum test and chi-squared test were used to calculate
differences amongst the different groups. Kaufman et al.
[68] presented their results in tabulated form comparing
the total number of teeth positive and negative for DH
at baseline, three, and eight weeks when assessed using
tactile or air stimuli. A graphical representation of results
was also depicted via combined line graphs to indicate the
difference between the three groups. A logit transform of the
proportion of the examined teeth (testing positive for DH)
was calculated; within group differences were calculated via
a 2-way analysis of variance and 𝑡-tests with the Bonferroni
correction were evaluated between group differences. The
Kruskal-Wallis, Friedman’s 2-way analysis of variance, and
chi-squared tests were used to analyse the questionnaire
results for the various time intervals.
8.2. Types of Treatment Intervention. In all the 5 included
studies, a daily home use of calcium sodium phosphosilicate
(Novamin) (Pradeep et al. [64], Pradeep and Sharma [65],
Litkowski and Greenspan [66]) and/or ACP (Ghassemi et al.
[67], Kaufman et al. [68]) (Tables 5 and 6). No studies for
HAP andCPP-ACP toothpastes howeverwere included in the
present review (Tables 3 and 4).
8.3. Clinical Methodology Used to Assess DH. Themost com-
monly used method of clinically assessing DH in these three
studies was an evaporative stimulus. This was conducted
using a controlled air pressure from a standard dental syringe
at 40–65 psi perpendicular to the tooth surface at a distance of
1–3mm [64, 65]. Litkowski and Greenspan [66] using similar
methodology reported a blast of cold air for one second.
The second most popular method of DH assessment was a
thermal stimulus via the application of 10mL of ice cold water
to the exposed root surface [64, 65]. Litkowski andGreenspan
[66] reported on using a tactile stimulus perpendicularly to
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the long axis of the tooth and directly onto the exposed root
surface. A Yeaple probe (XINIX Inc., Portsmouth, UK) was
calibrated to deliver 40 g force along the root surface when
assessing DH. Ghassemi et al. [67] used a thermal stimulus
of a cold air blast on exposed root surfaces and subsequently
recorded a VAS and Schiff score.
Kaufman et al. [68] assessed DH at baseline, three, and
eight weeks following the use of the three different treatment
modalities. Subjects were provided with a questionnaire at
each visit and were asked to rate their sensitivity as none
(0), mild (1), moderate (2), or severe (3). These investigators
used electrical, tactile, and air stimuli; the latter was used last
due to its ability to cause a prolonged painful response. To
evaluate an electrical stimulus, the sensitometer was used; its
tip was moistened with a conducting gel and then placed in
the midline of the enamel surface at the gingival 1/3 of the
tooth under test. The voltage was slowly increased until the
subject experienced a sensation at which point the stimulus
was stopped via a button controlled by the participant. Tactile
stimuli were assessed via the scratchometer (SUNY Stony
Brook, Stony Brook, NY). The stainless steel explorer tip was
moved mesiodistally along the CEJ at a fixed pressure until
the participant experienced sensitivity or if the pressure had
exceeded 80 centi-Newtons. The last stimulus used was a
response to a one-second blast of air from a dental air syringe
held 0.5 cm from the centre of the tooth. The participants
were asked to rate their response to the stimulus as 0—
no discomfort, 1—uncomfortable, 2—painful, or 3—painful
with persisting pain after stimulus was ceased. The three
different stimuli measured DH at the three and eight week
assessments; at baseline following the screening of suitable
patients and teeth, a DH assessment (by air and tactile
stimuli) was conducted on the selected teeth and patients
were subsequently accepted into the study.
8.4. Calibration and Examiner Training. Ghassemi et al. [67]
reported that their investigators were calibrated regarding the
DH assessment tests within the last year. None of the other
four studies stated or reported any calibration taking place
amongst clinicians [64–66, 68].
8.5. Compliance. Only two of the five papers reported on
compliance, for example, Ghassemi et al. [67] monitored
compliance by weighing the toothpaste at baseline, 4, and 8
weeks and by monitoring the subjects’ diaries (daily tooth
brushing regime including timings). The Litkowski and
Greenspan [66] study reported compliance by weighing the
toothpaste over the 8-week period; for example, the control
group used 142.4 g of toothpaste over the 8-week period
whereas participants in the 2.5% and 7.5% groups used 161.5 g
and 144.5 g of toothpaste, respectively.
9. Discussion
Dentine hypersensitivity (DH) is a commondental complaint
which may have a profound effect on an individual’s quality
of life [1, 2, 72]; however, DH tends to be an underestimated
condition due to underreporting by its sufferers and also the
difficulty in diagnosing it [6]. Pain experienced and reported
due to DH is subjective in nature and depends primarily on
the individuals’ previous experiences of pain; this can create
discrepancies in clinical trials involving DH prevalence.
Evaluating the latter for the purpose of clinical trials can be
complicated due to both the Hawthorne and placebo and
nonplacebo effects throughout the duration of the study [73].
The true placebo response is seen in participants whose pain
response or perception may change over a period of time
especially if they were participating in a clinical trial testing
for a desensitizing agent; these subjects are normally unaware
that they have been randomized in the control group. The
placebo effect has been reported to range from 20–60% from
the baseline measurements [74, 75]. The Hawthorne effect
can be described as the unconscious change in participant
behaviour due the mere knowledge of being observed during
a clinical trial. Bias can be introduced into clinical trials as
a result of a number of reasons: lack of statistical power,
for example, small sample size or lack of standardization of
the methodology, no allocation concealment, or improper
stratification and randomization of groups.
There is a plethora of remedies currently available for
both OTC and in-office alleviation of DH; however, none of
these products appear to be the “gold standard” in providing
a long term effective treatment to the problem [3, 5, 6].
Marketed products currently work either via their tubule
occlusion properties, for example, Novamin, ACP,HAP, CPP-
ACP, toothpastes and so forth, or via nerve desensitization,
for example, potassium technology.
The current review examined the available published lit-
erature (in English) on four marketed agents currently being
used to alleviate dental problems, namely, calcium sodium
phosphosilicate, (nano)hydroxyapatite crystals, amorphous
calcium phosphate, and casein phosphopeptide amorphous
calcium phosphate (now GC Toothmousse) toothpastes. Five
clinical trials were included following an extensive review
of the published literature description up to 31, December,
2012, three on calcium sodium phosphosilicate [64–66] and
two studies on ACP [67, 68]. None of the available literatures
on (nano)HAP or CPP-ACP were included in this review as
previously indicated (Tables 3 and 4).
One of the problems when evaluating the efficacy of
the selected products for the present review was that in
retrospect the criteria may have been too restrictive when
considering the studies with matched placebo controls. It
may therefore be argued that the inclusion of studies with
a valid negative control, for example, the same constituents
as the agent under test without the active ingredient, would
have allowed the authors to make an evaluation among
two or three comparable groups and hence any changes
or improvements in DH would be attributed to the active
ingredient under test. However, the rationale for conducting
this review was to determine whether the active ingredient in
the tested toothpastes delivers efficacy in the reduction of DH
which is the basis of the claims made for these toothpastes
by the manufacturers [7]. Other benefits attributed to these
toothpastes such as antiplaque, anticaries, and reduction in
DH following vital tooth bleaching have not been considered
in this review.
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Of the 34 relevant Novamin studies that were retrieved by
the authors, the majority of these studies were excluded [11–
41] (Table 1). only three RCTs were included into the present
review; Pradeep et al. [64], Pradeep and Sharma [65], and
Litkowski and Greenspan [66].
Pradeep et al. [64] conducted a triple-masked ran-
domised controlled trial to evaluate and compare the efficacy
of (a) 5% potassium nitrate (KNO
3
) (positive control), (b)
5% calcium sodium phosphosilicate (test), (c) 3.85% amine
fluoride, and (d) placebo (negative control) toothpastes on
DH alleviation. The randomisation of groups was conducted
via computer generation and investigators, participants, and
statisticians were all blinded as to which treatment each
group they would be allocated to. The toothpastes were
dispensed in identical white tubes which were then labelled
as A, B, C, or D; the identity of each tube was revealed to
the investigators only after the last assessment had taken
place.This process was conducted in this manner tomaintain
allocation concealment and to prevent the introduction of
any bias or confounding factors in the trial. Sensitivity assess-
ment was carried out via evaporative (air blast) and ther-
mal (10mL of ice cold water) stimuli. Participants were
instructed on how to use the VAS (0–10 cm) and their
self-reported DH assessment data were analysed by the
statisticians. Assessments were carried out at baseline, two,
and six weeks after treatment and statistically significant
improvements in DH were observed in all four groups; the
most significant improvement was observed in the calcium
sodium phosphosilicate group. KNO
3
was used as a positive
control due to its universal market availability (particularly
in the USA). Fluorides such as NaF or stannous fluoride have
been previously shown to be effective in the treatment of
DH via their ability to deposit calcium fluoride and occlude
the patent dentine tubules. The placebo group of individuals
may also respond positively to the treatment; the reasons for
this may be either placebo or Hawthorne effects or even the
participants’ desire to impress or please the investigators and
regression to the mean or mode.
Pradeep et al. [64] failed to report on any calibration
among participants and their recording of DH which would
be an important part of this trial due to the subjectivity of
pain. The authors did not disclose any information as to
how many investigators or statisticians took part in the study
and statistical analysis followed was somewhat unclear. One
of the limitations of this study was the lack of description
of the constituents of the placebo group. It would therefore
be logical to assume that the placebo control may be one
of the following: no treatment, distilled water, or even the
same constituents as the test groups but lacking the active
ingredients. If the latter was the true constituent of the
placebo group, then this RCTwas correctly included into this
review.
Pradeep and Sharma [65] conducted a triple-masked ran-
domization controlled clinical trial to evaluate and compare
the efficacy of (a) 5% calcium sodium phosphosilicate, (b)
5% potassium nitrate (positive control), and (c) toothpaste
with same contents as (a) but without the active ingredient
(negative control) on DH alleviation. Participants were allo-
cated into individual groups by a lottery method; however,
no information was obtained from the full text of this study
as to who carried out the randomization and how blinding of
investigators had taken place.The toothpastes were dispensed
in tubes labelled as A, B, and C; the contents of which were
disclosed to the investigators after completion of statistical
analysis. Sensitivity assessments were conducted using the
same methods as in Pradeep et al. [64] at baseline, two, and
six weeks after treatment and hence the same limitations
were introduced due to the limited duration of the study
(6 weeks). Statistically significant improvements to DH were
observed in all three groups; the CSPS group exhibited the
most significant improvement out of all three treatment
modalities. The changes observed in the placebo group were
again attributed to the placebo or Hawthorne effects. As
previouslymentioned, the fact that the inclusion of a negative
control of the same composition as the test toothpaste but
without the active ingredient was used enabled the authors
to make valid conclusions (given that the groups involved
appeared to be comparable in all aspects) that any changes
in DH could be attributed to the active ingredient in group
(a). No information however was available on any calibration
between the investigators and the statistical analyses used did
not appear to be consistent with good statistical practice.
Litkowski and Greenspan [66] in their first pilot study for
CSPS randomly allocated 66 participants into three groups.
The investigators claimed that this trial was double-blinded in
nature; however, no information was available to determine
how the investigators and volunteers were blinded. There
were no details on allocation concealment and this could
potentially introduce bias and confounding factors. The aim
of this study was to evaluate and compare the efficacy of
(a) 2.5% CSPS, (b) 7.5% CSPS, and (c) a placebo control
on DH management. DH assessments were conducted using
tactile (Yeaple probe) and evaporative (one second blast of
air) stimuli at baseline, two, four, and eight weeks after
treatment. The results were presented in a tabulated form;
the 7.5% CSPS group exhibited the greatest improvement in
DH from baseline whereas placebo and 2.5% CSPS exhibited
similar % improvement at the end of the 8-week period.
Limitations involved with the Litkowski and Greenspan [66]
study involved (a) themethod of randomization; how did this
take place and who carried it out, (b) blinding of investigators
and participants was not described, (c) no description was
given regarding the volunteers’ age range, M : F ratio, (d) no
calibration methods were mentioned, (e) statistical analyses
did not conform with good statistical practice, and (f) reason
for choosing particular sample size was not mentioned and
the eligibility criteria were not clearly described to the reader.
The most important discrepancy in this RCT would have to
be the lack of description of the constituents of the placebo
group; the authors omitted this information in their study and
hence groups a and b could not potentially be comparable to
group c.The reason for inclusion of this RCT into the present
review was initially in doubt due to the lack of clarity of the
control group; it may be speculated that the placebo control
group consisted of the same constituents as the test groups
but without the active ingredients.
Of the included studies, only the Litkowski and Green-
span [66] study recorded any patient compliance during
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the clinical trial and this was by weighing the toothpaste
before and after usage by the patients.
One of the problems in evaluating the efficacy of the
Novamin dentifrice or toothpaste was that there are lim-
ited published clinical data that consistently supported the
product. For example, in the included studies, Litkowski
and Greenspan [66] examined two different concentrations,
namely 2.5% and 7.5% bioglass against a placebo (0% bio-
glass). A 5%Novamin version is currently on themarket even
though that Litkowski and Greenspan [66] study reported
that the 7.5% Novamin was superior to 2.5%. There does
not appear to be any published clinical studies comparing
5% to 7.5% Novamin. Furthermore, the formulations in the
three studies and the current formulation are different; for
example, there was no fluoride in the earlier formulations
of Novamin although a later formulation included 0.24%
stannous fluoride and the current commercially available
Novamin contains a sodium monofluorophosphate (MFP)
(1450 ppm). The different fluoride ingredient and concen-
tration of Novamin in the currently commercially available
versionmay be due to either regulatory or formulation issues.
One of the problems in formulating a toothpaste containing
Novamin is related to its ability to absorb moisture from
the atmosphere and the current formulation is anhydrous in
nature.
Most of the ACP studies retrieved (apart from the 2
included studies) were excluded as previously indicated in
Table 2. Of the 10 studies, four were in vitro investigations
examining the effects of ACP on dentine tubule occlusion
and hydraulic conductance [42–45]. randomized trials, for
example, the Fiocchi et al. [46] and Geiger et al. [49] studies,
lacked negative controls and Giniger et al. [47] investigated
the remineralization potential of ACP following vital tooth
bleaching and the study was subsequently excluded. Yates et
al. [50] conducted a double-blind randomized split mouth
study and applied intraoral ACP to one side of the oral
cavity and a control dentifrice to the contralateral side.
All applications were conducted in office and the results
demonstrated that the test (ACP) toothpaste did not provide
any significantly superior results compared to a control
toothpaste. Of those studies included in the present review,
Ghassemi et al.’s [67] study was a double-blind, two-phase
RCT which fulfilled all the criteria of the present review; the
duration was longer than 6 weeks and the sample size was
sufficient to provide a significant result; the examiners were
also calibrated prior to the study, and the test group contained
the ingredient under investigation (delivered calcium, phos-
phate, and 0.24% NaF) whereas the control group delivered
an identical level of NaF to the participants. During the first
8-week phase of the trial, 208 participants were stratified
according to their VAS scores, gender, and age; theywere then
randomly assigned to either the ACP (plus 0.24%NaF) group
or control group (0.24%NaF). Allocation concealment was
achieved via dispensing both products into identical white
coded tubes; however, there was no detail as to who carried
out the concealment and randomisation of groups. VAS and
Schiff scores were recorded at baseline, four, and eight weeks.
During the second phase of the trial, subjects from the test
group were recruited for a second 8-week study to assess
the persistence of DH via the home use of the control
toothpaste (90 of 103 subjects took part). The authors con-
cluded that the test toothpaste provided superior results when
compared to the control (fluoride only) group; however, DH
improvement had also been observed in the control group
and this again was attributed to the placebo or Hawthorne
effects.
Kaufman and coworkers [68] conducted a double-blind
randomized clinical trial; however, the authors did not report
on how the randomization and allocation concealment was
conducted. There was no mention of the participant age
range and there were significantly higher proportions of
females compared to males (72% versus 28%). The authors
screened participants for DH by tactile and evaporative
stimuli; however, they recorded DH at three and eight weeks
using electrical, tactile, and evaporative stimuli. One of
the problems with this study particularly when compared
to the other included studies was that the electrical and
mechanical stimuli used in the assessment were used solely
by the Kauffman/Kleinberg group at Stony Brook University,
USA, and rarely used outside that Institute, and the other
studies recorded using similar tactile and thermal stimuli.
The use of an electrical stimulus in this type of student has
been questioned as it is based on voltage and not constant
current which has been considered more appropriate if using
an electrical stimulus [73]. Furthermore, the results were
presented in tabulated form for tactile or air stimuli; the
authors did not provide sufficient information on either the
air or tactile stimuli and therefore any comparisonwith intra-
operative results would be problematic. The three treatment
groups were also unclear; the authors did not mention the
constituents of group A which acted as the control group or
the % of fluoride present. These observations may therefore
limit the conclusions related to the efficacy of the products
tested in this study.
There were eight nano-HAP studies which were excluded
because they were in vitro investigations (effect on dentine
tubule occlusion) and therefore did not meet the inclusion
criteria [51–58] (Table 3). Two randomized controlled trials
[51, 52] investigating the effects of nano-HAP on DH were
also retrieved and subsequently excluded from the present
review due to the fact that (1) the desensitizing agents were
applied in office and as a dry sol gel or liquid precipitate form
and not as a OTC dentifrice or toothpaste [59] and due to
(2) the lack of a negative control respectively [60]. A further
study by Browning et al. [61] investigating the effect of HAP
in DH attributed to dental bleaching was also excluded from
the present review as this mechanism has been considered to
be a completely distinct mechanism to DH [48].
CPP-ACP also known as GC tooth mousse has been
used for remineralizing a demineralized lesion on the tooth
surface. The two studies retrieved for the purpose of the
present review (Gandolfi et al. [62] and Ranjitkar et al. [63])
were excluded as they were in vitro studies (Table 4).
10. Conclusions
One of the major challenges encountered in conducting
this present review was the large heterogeneity among
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the different included and excluded studies in terms of sample
size, duration of studies, placebo and nonplacebo controls,
methodology in assessing DH, lack of detail on randomiza-
tion or allocation concealment, and so forth. Cummins [76]
previously suggested that considerable variation existed in
the design and conduct of DH studies before 1997 which
could invariably introduce bias into a systematic reviewwhen
different studies are compared. Studies conducted after 1997
generally follow the Holland et al. [69] guidelines when
assessing various desensitizing agents [5] and one of the
advantages of the studies using these guidelines is that this
will enable the investigators to compare studies which have a
similar methodology to evaluate a desensitizing agent.
The results from the small number of included cal-
cium sodium phosphosilicate (CSPS) studies have limited
any definitive conclusion on its efficacy in alleviating DH
although it can be acknowledged from these studies that
CSPSmay have some effect on DH alleviation. A similar con-
clusion may also be applied to the efficacy of ACP containing
toothpastes with only one included study in the present
review.
None of the studies retrieved for inclusion in the present
review directly compared the four selected four products
using the same study design and methodology. Furthermore,
there were no randomized controlled trials that compared at
least two of the products in the present review. No conclu-
sions can therefore be made from any direct comparison of
CSPS,ACP, (nano)HAP, orACP toothpastes and their efficacy
on DH in the included studies.
No conclusions can be made from this review on the
efficacy of any of the other selected two agents; (nano)HAP
and CPP-ACP toothpastes due to the lack of sufficient evi-
dence to support any efficacy in reducing DH.
The conclusions from the present review would therefore
suggest that there is a paucity of well-conducted DH studies
based on the Holland et al. [69] recommendations when
conducting studies of this nature.
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